Merck + Co., Inc.

Merck Sharp + Dohme Corp.

Jaime Lynn Bunda

Sander G Mills

Jinlong Jiang

Robert J DeVita

Craig William Lindsley

Michael P Dwyer

Gregori J Morriello

Richard Berger

William D Shipe

Kausik K Nanda

Lehua Chang

Yili Chen

Ming Wang

Ashley Forster

Feng Yang

Robert J Devita

The present invention is directed to benzyl-substituted quinolone compounds of general formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of diseases in which the M1 receptor is involved.

Benzyl-substituted quinolone M1 receptor positive allosteric modulators

The present invention is directed to certain hydroisoindoline compounds of formula I which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, urinary incontinence, depression, and anxiety. 

Hydroisoindoline tachykinin receptor antagonists

The present invention is directed to certain hydroisoindoline compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, urinary incontinence, depression, and anxiety.

Growing community of inventors

Holland, PA, United States of America

Jaime Lynn Bunda